SCHEMBL25569811

SCHEMBL25569811

CCC(=O)Cc1ccc2c(c1)SCC2

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 3/20 0.36
IAPP P10997 1/20 0.33
LMNA P02545 4/20 0.33
ALDH1A1 P00352 4/20 0.33
MAPT P10636 2/20 0.33
NPC1 O15118 2/20 0.32
KDM4E B2RXH2 1/20 0.32
HSD17B10 Q99714 1/20 0.32
CTSL P07711 1/20 0.32
RYR2 Q92736 1/20 0.32
RAB9A P51151 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2D6 P10635 1/20 0.31
HPGD P15428 1/20 0.31
CYP2C19 P33261 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
ITK Q08881 1/20 0.31
MAPK8 P45983 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25569783 0.88 LMNA (0.35) AKR1B1IAPPLMNAALDH1A1MAPT
SCHEMBL25569805 0.84 AKR1B1 (0.38) AKR1B1LMNAALDH1A1MAPTNPC1
SCHEMBL9548959 0.83 AKR1B1 (0.51) AKR1B1LMNAALDH1A1MAPTKDM4E
SCHEMBL25569855 0.81 AKR1B1 (0.36) AKR1B1LMNAALDH1A1MAPTCYP1A2
SCHEMBL12694254 0.79 CTSL (0.43) LMNAALDH1A1MAPTNPC1KDM4E
SCHEMBL25569860 0.77 MTNR1A (0.40) AKR1B1ALDH1A1MAPT
SCHEMBL25569856 0.76 HDAC4 (0.37) AKR1B1LMNAALDH1A1MAPTNPC1
SCHEMBL10388342 0.76 CNR1 (0.39) ALDH1A1CTSL
SCHEMBL7241941 0.75 GRIN2B (0.33) AKR1B1LMNAMAPTHSD17B10CTSL
SCHEMBL25569816 0.75 ATM (0.44) LMNAALDH1A1MAPTNPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159487-A1 ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT TACTOGEN INC (US) 2023-05-25 US disclosed
US-20230159487-A1 ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT TACTOGEN INC (US) 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159487-A1 ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT SLC6A3, CREBBP, SLC1A2 AKR1B1 3863/4885IAPP 4444/4885LMNA 4660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.